Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanoma.

Mol Ther Nucleic Acids · 2024 · PMC11334831 · PMID 39165562

Europe PMC DOI

hedged sentence

0.0722

closest p · 1.4× alpha

0.0722

boldest claim

The sentences

failed to reach statistical significancep = 0.0722so close (0.05 < p ≤ 0.1)

Tumor progression was delayed by intratumoral 3pRNA injection in mice treated with dabrafenib and trametinib in combination, but the difference failed to reach statistical significance ( Figure S1 , p = 0.0722, unadjusted Gehan-Breslow-Wilcoxon test).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.